Oxbryta

Sickle cell community scrambles to find safe plan after a drug is pulled from the market
Stat
Mon, 09/30/24 - 09:56 am
Pfizer
sickle cell disease
Oxbryta
patients
Pfizer issues global market withdrawal of sickle cell disease therapy Oxbryta
Fierce Pharma
Wed, 09/25/24 - 10:29 pm
Pfizer
sickle cell disease
Oxbryta
We finally have new drugs for sickle cell disease. Why are so few patients taking them?
Stat
Mon, 12/19/22 - 11:13 am
sickle cell disease
patients
Global Blood Therapeutics
Oxbryta
Pfizer buys sickle cell drugmaker Global Blood for $5.4B
BioPharma Dive
Mon, 08/8/22 - 10:29 am
Pfizer
Global Blood Therapeutics
M&A
sickle cell disease
Oxbryta
Pfizer, riding high on COVID windfall, eyes $5B play for Global Blood Therapeutics
Fierce Pharma
Sun, 08/7/22 - 11:27 pm
Pfizer
Global Blood Therapeutics
M&A
Oxbryta
Global Blood takes on gene therapy
EP Vantage
Thu, 10/28/21 - 10:36 am
Global Blood Therapeutics
GBT021601
Oxbryta
gene therapy
ASH2021
sickle cell disease
Novartis, GBT sickle cell drugs face coverage hurdles as gene therapy threats loom: survey
Fierce Pharma
Wed, 06/30/21 - 12:09 am
Novartis
Adakveo
Global Blood Therapeutics
Oxbryta
sickle cell disease
gene therapy
New sickle cell drugs priced too high, ICER says
BioPharma Dive
Fri, 03/13/20 - 12:43 pm
sickle cell disease
drug pricing
ICER
Novartis
Global Blood Therapeutics
RWE
Adakveo
Oxbryta
Sickle Cell Disease: After Years Of Neglect Some Promise For Sufferers
Forbes
Mon, 02/17/20 - 10:26 am
sickle cell disease
Oxbryta
Adakveo
Endari
olinciguat
CRISPR
GBT takes a page from HIV playbook as it embarks on Oxbryta launch
Fierce Pharma
Thu, 02/13/20 - 11:31 pm
Global Blood Therapeutics
drug launches
Oxbryta
sickle cell disease
HIV
Trifecta of sickle cell disease therapies extend life expectancy, but are not cost-effective — ICER
Endpoints
Fri, 01/24/20 - 10:30 am
ICER
sickle cell disease
Novartis
Adakveo
Global Blood Therapeutics
Oxbryta
Emmaus Life Sciences
Endari
3 Rare Disease Drug Launches to Watch in 2020
Motley Fool
Sat, 01/4/20 - 07:38 pm
Global Blood Therapeutics
sickle cell disease
Oxbryta
Novartis
SCD
Adakveo
Alnylam
Givlaari
acute hepatic porphyria
FDA
5 New Drug Approvals the FDA Gave Top Priority
Motley Fool
Sat, 11/30/19 - 11:22 pm
FDA
drug approvals
Global Blood Therapeutics
Oxbryta
Alnylam
Givlaari
BeiGene
Brukinsa
Vertex Pharmaceuticals
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
RAPS.org
Wed, 11/27/19 - 12:39 pm
FDA
Vertex Pharmaceuticals
Trikafta
Novartis
Adakveo
Alnylam
Givlaari
BeiGene
Brukinsa
Global Blood Therapeutics
Oxbryta
drug approvals
Global Blood’s Sickle Cell Drug Wins FDA Approval Ahead of Schedule
Xconomy
Mon, 11/25/19 - 10:14 pm
Global Blood Therapeutics
FDA
sickle cell disease
voxelotor
Oxbryta